Vivosim Labs (VIVS) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Vivosim Labs in October 2026.
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company, which is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company also advances product candidates to treat inflammatory bowel disease (IBD) discovered and developed using its complex human tissue intestinal models.
About This Stock
VIVOSIM LABS INC
VIVS
Current Price
$0.15
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Ticker
VIVS
Market Cap
$2.46M
Potential 12 Month Profit
N/A
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Financial Health
Organovo is generating low revenue, but has a strong cash flow and gross margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.